Impact of genetic polymorphisms in the clinical response of oral inhibitors of the platelet P2Y12 adenosine diphosphate (ADP) receptor

被引：0

作者：

Simon, T. ^{[1
]}

机构：

[1] Univ Paris 06, AP HP, Serv Pharmacol, F-75252 Paris 05, France

来源：

ANNALES DE CARDIOLOGIE ET D ANGEIOLOGIE | 2010年 / 59卷

关键词：

Pharmacogenetics; Antiplatelet; Thienopyridine; Prognosis; Cardiovascular disease; PERCUTANEOUS CORONARY INTERVENTION; OF-FUNCTION POLYMORPHISM; STENT THROMBOSIS; ANTIAGGREGATING ACTIVITY; CYP2C19; GENOTYPE; CLOPIDOGREL; OUTCOMES; PRASUGREL; THERAPY; TRIAL;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Dual antiplatelet therapy with clopidogrel combined to aspirin reduces ischemic events in a wide range of patients with cardiovascular disease. However, a large interindividual variability has been observed in the pharmacodynamics response of clopidogrel with lower platelet inhibition associated with increased risk for major adverse cardiovascular events. Multiple mechanisms have been proposed for the variable response to clopidogrel, among which the impact of pharmacogenetic seems to play an important role. This article reviews the role of genetic polymorphisms in the clinical impact of oral inhibitors of the platelet P2Y12 adenosine diphosphate (ADP) receptor. (C) 2010 Elsevier Masson SAS. All rights reserved.

引用

页码：S90 / S94

页数：5

共 31 条

[1]

Bonello L, 2010, J AM COLL CARDI 0730

[2] Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel [J].

Brandt, J. T. ;

Close, S. L. ;

Iturria, S. J. ;

Payne, C. D. ;

Farid, N. A. ;

Ernest, C. S., II ;

Lachno, D. R. ;

Salazar, D. ;

Winters, K. J. .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2007, 5 (12) :2429-2436

[3] The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin [J].

Clarke, TA ;

Waskell, LA .

DRUG METABOLISM AND DISPOSITION, 2003, 31 (01) :53-59

[4] Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study [J].

Collet, Jean-Philippe ;

Hulot, Jean-Sebastien ;

Pena, Anna ;

Villard, Eric ;

Esteve, Jean-Baptiste ;

Silvain, Johanne ;

Payot, Laurent ;

Brugier, Delphine ;

Cayla, Guillaume ;

Beygui, Farzin ;

Bensimon, Gilbert ;

Funck-Brentano, Christian ;

Montalescot, Gilles .

LANCET, 2009, 373 (9660) :309-317

[5] Relation of Cytochrome P450 2C19 Loss-of-Function Polymorphism to Occurrence of Drug-Eluting Coronary Stent Thrombosis [J].

Giusti, Betti ;

Gori, Anna Maria ;

Marcucci, Rossella ;

Saracini, Claudia ;

Sestini, Ilaria ;

Paniccia, Rita ;

Buonamici, Piergiovanni ;

Antoniucci, David ;

Abbate, Rosanna ;

Gensini, Gian Franco .

AMERICAN JOURNAL OF CARDIOLOGY, 2009, 103 (06) :806-811

[6] Randomized Double-Blind Assessment of the ONSET and OFFSET of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in Patients With Stable Coronary Artery Disease The ONSET/OFFSET Study [J].

Gurbel, Paul A. ;

Bliden, Kevin P. ;

Butler, Kathleen ;

Tantry, Udaya S. ;

Gesheff, Tania ;

Wei, Cheryl ;

Teng, Renli ;

Antonino, Mark J. ;

Patil, Shankar B. ;

Karunakaran, Arun ;

Kereiakes, Dean J. ;

Parris, Cordel ;

Purdy, Drew ;

Wilson, Vance ;

Ledley, Gary S. ;

Storey, Robert F. .

CIRCULATION, 2009, 120 (25) :2577-U103

[7] Cytochrorne P4502C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects [J].

Hulot, Jean-Sebastien ;

Bura, Alessandra ;

Villard, Eric ;

Azizi, Michel ;

Remones, Veronique ;

Goyenvalle, Catherine ;

Aiach, Martine ;

Lechat, Philippe ;

Gaussem, Pascale .

BLOOD, 2006, 108 (07) :2244-2247

[8] Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis:: a double-blind comparison to clopidogrel with aspirin [J].

Husted, S ;

Emanuelsson, H ;

Heptinstall, S ;

Sandset, PM ;

Wickens, M ;

Peters, G .

EUROPEAN HEART JOURNAL, 2006, 27 (09) :1038-1047

[9] A clinical trial comparing three antithrombotic drug regimens after coronary-artery stenting [J].

Leon, MB ;

Baim, DS ;

Popma, JJ ;

Gordon, PC ;

Cutlip, DE ;

Ho, KKL ;

Giambartolome, A ;

Diver, DJ ;

Lasorda, DM ;

Williams, DO ;

Pocock, SJ ;

Kuntz, RE .

NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (23) :1665-1671

[10] Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis [J].

Mega, Jessica L. ;

Close, Sandra L. ;

Wiviott, Stephen D. ;

Shen, Lei ;

Walker, Joseph R. ;

Simon, Tabassome ;

Antman, Elliott M. ;

Braunwald, Eugene ;

Sabatine, Marc S. .

LANCET, 2010, 376 (9749) :1312-1319

← 1 2 3 4 →